UCAB

UCB is a global biopharmaceutical company headquartered in Brussels, Belgium, specializing in the discovery and development of innovative medicines for severe diseases. The company focuses primarily on two main therapeutic areas: neurology and immunology, with a growing presence in bone health and rare diseases. UCB's commercial portfolio includes blockbuster treatments such as Cimzia for inflammatory diseases and Vimpat and Keppra for epilepsy. Recent growth has been driven by the launch of Bimzelx for psoriasis and the approval of treatments for generalized myasthenia gravis. UCB maintains a robust R&D pipeline and actively pursues strategic acquisitions and partnerships to expand its technological capabilities in areas like gene therapy and targeted protein degradation.